Filing Details

Accession Number:
0001104659-15-004406
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-01-26 13:46:04
Reporting Period:
2015-01-22
Filing Date:
2015-01-26
Accepted Time:
2015-01-26 13:46:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1135906 Epirus Biopharmaceuticals Inc. EPRS Pharmaceutical Preparations (2834) 043514457
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1423641 Montreux Equity Partners Iv Lp One Ferry Building, Suite 255
San Francisco CA 94111
No No Yes No
1548152 Montreux Equity Partners V, L.p. One Ferry Building, Suite 255
San Francisco CA 94111
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2015-01-22 14,130 $6.30 1,938,316 No 4 S Direct
Common Stock Disposition 2015-01-23 8,400 $6.27 1,929,916 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 271,476 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.36, inclusive. The Reporting Person undertakes to provide to EPIRUS Biopharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer or the staff of the Securities and Exchange Commission (the "Commission"), upon request, full information regarding the number of shares sold at each separate price within the range reported.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.25 to $6.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Commission, upon request, full information regarding the number of shares sold at each separate price within the range reported.
  3. The securities reported herein reflect the 1-for-10 reverse stock split effected by the Issuer on July 16, 2014.
  4. Represents shares of common stock ("Common Stock") of the Issuer directly held by Montreux Equity Partners IV, L.P. John J. Savarese, M.D., Howard D. Palefsky and Daniel K. Turner III are the managers of Montreux Equity Management IV, LLC, which is the sole general partner of Montreux Equity Partners IV, L.P. By reason of these relationships, Montreux Equity Management IV, LLC, Dr. Savarese, Mr. Palefsky and Mr. Turner may be deemed to beneficially own the securities reported herein. Each of Montreux Equity Management IV, LLC, Dr. Savarese, Mr. Palefsky and Mr. Turner disclaims beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein.
  5. Represents shares of Common Stock of the Issuer directly held by Montreux Equity Partners V, L.P. Daniel K. Turner III is the sole manager of Montreux Equity Management V, LLC, which is the sole general partner of Montreux Equity Partners V, L.P. By reason of these relationships, Montreux Equity Management V, LLC and Mr. Turner may be deemed to beneficially own the securities reported herein. Each of Montreux Equity Management V, LLC and Mr. Turner disclaims beneficial ownership of such securities, except to the extent of their respective pecuniary interests therein.